Quoin Pharmaceuticals Ltd. has announced the filing of U.S. and International patent applications for new topical formulations of rapamycin aimed at treating rare diseases such as microcystic ...
The drug inhibits progression of epidermolysis bullosa in skin. Recessive dystrophic pidermolysis bullosa (RDEB) leads to excessive deposition of fibrosis (COL I) in the skin in response to skin ...
Quoin Pharmaceuticals Ltd. has filed a U.S. patent application for new topical formulations aimed at treating several skin diseases, specifically Netherton Syndrome (NS) and Peeling Skin Syndrome. The ...
Quick Take Snakes usually shed their skin in one complete piece, while lizards and amphibians shed in messy, irregular ...
Steven Daniel Daveluy, MD, FAAD, discussed how artificial intelligence (AI) can leverage extensive patient data and guide dermatologists to improve early diagnosis and treatment of rare dermatological ...
Almost everyone carries microscopic mites on their skin. They live inside pores and hair follicles, feeding on skin oils and ...
Overall Count and Share for 'European Reference Network for Rare and Undiagnosed Skin Disorders (ERN-Skin)' based on the 12-month time frame mentioned above. Note: Articles may be assigned to more ...
Palvella’s recently expanded rare disease pipeline now comprises QTORIN™-derived product candidates advancing in four serious, rare skin diseases that currently have no FDA-approved therapies Top-line ...
Patients suffering from rare and life-threatening skin disorders may soon see hope, as the national policy for rare diseases, which currently covers 63 conditions, is set to be expanded to include ...
The webinar will explore PC111, a novel monoclonal antibody drug candidate with the potential to transform the treatment landscape for Pemphigus Vulgaris and Stevens-Johnson Syndrome/Toxic Epidermal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results